Clinical Trial

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Name: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) — clinical trial record (NCT07684144)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

Trial Details

NCT Number	NCT07684144
Lead Sponsor	Amgen
Conditions	Obesity, Overweight, Diabetes Mellitus, Type 2
Enrollment	950 participants
Start Date	2026-07-29
Primary Completion	2027-12-26 (estimated)
Study Completion	2028-03-19 (estimated)
Updated on ClinicalTrials.gov	2026-07-06